Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Cancers, 12, 2
- Keyword
-
-
- Event
-
Veröffentlichung
- (where)
-
Greifswald
- (who)
-
Universität Greifswald
- (when)
-
2020
- Creator
-
Ladenstein, Ruth
Pötschger, Ulrike
Valteau-Couanet, Dominique
Luksch, Roberto
Castel, Victoria
Ash, Shifra
Laureys, Geneviève
Brock, Penelope
Michon, Jean Marie
Owens, Cormac
Trahair, Toby
Chi Fung Chan, Godfrey
Ruud, Ellen
Schroeder, Henrik
Beck-Popovic, Maja
Schreier, Guenter
Loibner, Hans
Ambros, Peter
Holmes, Keith
Castellani, Maria Rita
Gaze, Mark N.
Garaventa, Alberto
Pearson, Andrew D.J.
Lode, Holger N.
- DOI
-
10.3390/cancers12020309
- URN
-
urn:nbn:de:gbv:9-opus-35986
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:52 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ladenstein, Ruth
- Pötschger, Ulrike
- Valteau-Couanet, Dominique
- Luksch, Roberto
- Castel, Victoria
- Ash, Shifra
- Laureys, Geneviève
- Brock, Penelope
- Michon, Jean Marie
- Owens, Cormac
- Trahair, Toby
- Chi Fung Chan, Godfrey
- Ruud, Ellen
- Schroeder, Henrik
- Beck-Popovic, Maja
- Schreier, Guenter
- Loibner, Hans
- Ambros, Peter
- Holmes, Keith
- Castellani, Maria Rita
- Gaze, Mark N.
- Garaventa, Alberto
- Pearson, Andrew D.J.
- Lode, Holger N.
- Universität Greifswald
Time of origin
- 2020
Other Objects (12)
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
The trial
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program
The trial
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR
Understanding and Exploiting MYCN Addiction in High-Risk Neuroblastoma Using the Example of CDK13
Functional validation of novel target structures for treatment of high-risk neuroblastoma
MCM complex as a critical node in the miR-183 signaling network of high-risk neuroblastoma cells
The function of JAGGED1 in neuroblastoma
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Genetic alterations and resectability predict outcome in patients with neuroblastoma assigned to high-risk solely by MYCN amplification
The future of affordable cancer immunotherapy
Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: a compassionate use program